$CTMX surged up to 250% in one hour 05/01/2024
Good day for those day traders who focused on $CTMX (Cytomx Therapeutics inc). After the market opened, during the first 20 min or so, 20 million shares were sold and its price dropped from 100% all the way to close to 50% which certainly disappointed many day traders and sold their positions. Good thing is that there are not so many competitors today when the overall stock market is almost all red. So soon enough the price started surging all the way to about 250%.
The catalyst is an early stage trial of an experimental drug CX-904 which was to be tested for its safety profile and efficacy. CX-904 is a t cell activist targeting EGFR positive tumors. The phase 1a trial data are not complete as yet. But again there was no competition today.
Press Release Details
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
May 1, 2024 at 8:00 AM EDT Download PDF
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -
- Management to hold conference call at5 p.m. EDT/2 p.m. PDTonMay 8th-
SOUTH SAN FRANCISCO, Calif.,May 01, 2024(GLOBE NEWSWIRE) --CytomX Therapeutics, Inc.(Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update onWednesday, May 8, 2024, after the close ofU.S.markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas,Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
PROBODY is aU.S.registered trademark ofCytomX Therapeutics, Inc.
Company Contact:
Chris Ogden
SVP, Finance and Accounting
cogden@cytomx.com
Investor Contact:
Stern Investor Relations
Stephanie Ascher
stephanie.ascher@sternir.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com